Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Medical Device Validation & Verification Market, By Therapeutic Area
7.1. Medical Device Validation & Verification Market, By Therapeutic Area Type, 2020-2030
7.1.1. Cardiovascular
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Dermatology
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Orthopedics
7.1.3.1. Market Revenue and Forecast (2016-2030)
7.1.4. Nephrology
7.1.4.1. Market Revenue and Forecast (2016-2030)
7.1.5. Respiratory
7.1.5.1. Market Revenue and Forecast (2016-2030)
7.1.6. Neurology
7.1.6.1. Market Revenue and Forecast (2016-2030)
7.1.7. Oncology
7.1.7.1. Market Revenue and Forecast (2016-2030)
7.1.8. ENT
7.1.8.1. Market Revenue and Forecast (2016-2030)
7.1.9. Others
7.1.9.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Medical Device Validation & Verification Market, By Application
8.1. Medical Device Validation & Verification Market, By Application, 2020-2030
8.1.1. Diagnostics
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Therapeutic
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Implants
8.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Medical Device Validation & Verification Market, By Technology
9.1. Medical Device Validation & Verification Market, By Technology, 2020-2030
9.1.1. Mechanical testing
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Biological
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. EMC/ECI
9.1.3.1. Market Revenue and Forecast (2016-2030)
9.1.4. Electrical Safety Testing
9.1.4.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Medical Device Validation & Verification Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.1.2. Market Revenue and Forecast, By Application (2016-2030)
10.1.3. Market Revenue and Forecast, By Technology (2016-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.1.4.2. Market Revenue and Forecast, By Application (2016-2030)
10.1.4.3. Market Revenue and Forecast, By Technology (2016-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.1.5.2. Market Revenue and Forecast, By Application (2016-2030)
10.1.5.3. Market Revenue and Forecast, By Technology (2016-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.2.2. Market Revenue and Forecast, By Application (2016-2030)
10.2.3. Market Revenue and Forecast, By Technology (2016-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.2.4.2. Market Revenue and Forecast, By Application (2016-2030)
10.2.4.3. Market Revenue and Forecast, By Technology (2016-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.2.5.2. Market Revenue and Forecast, By Application (2016-2030)
10.2.5.3. Market Revenue and Forecast, By Technology (2016-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.2.6.2. Market Revenue and Forecast, By Application (2016-2030)
10.2.6.3. Market Revenue and Forecast, By Technology (2016-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.2.7.2. Market Revenue and Forecast, By Application (2016-2030)
10.2.7.3. Market Revenue and Forecast, By Technology (2016-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.3.2. Market Revenue and Forecast, By Application (2016-2030)
10.3.3. Market Revenue and Forecast, By Technology (2016-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.3.4.2. Market Revenue and Forecast, By Application (2016-2030)
10.3.4.3. Market Revenue and Forecast, By Technology (2016-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.3.5.2. Market Revenue and Forecast, By Application (2016-2030)
10.3.5.3. Market Revenue and Forecast, By Technology (2016-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.3.6.2. Market Revenue and Forecast, By Application (2016-2030)
10.3.6.3. Market Revenue and Forecast, By Technology (2016-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.3.7.2. Market Revenue and Forecast, By Application (2016-2030)
10.3.7.3. Market Revenue and Forecast, By Technology (2016-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.4.2. Market Revenue and Forecast, By Application (2016-2030)
10.4.3. Market Revenue and Forecast, By Technology (2016-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.4.4.2. Market Revenue and Forecast, By Application (2016-2030)
10.4.4.3. Market Revenue and Forecast, By Technology (2016-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.4.5.2. Market Revenue and Forecast, By Application (2016-2030)
10.4.5.3. Market Revenue and Forecast, By Technology (2016-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.4.6.2. Market Revenue and Forecast, By Application (2016-2030)
10.4.6.3. Market Revenue and Forecast, By Technology (2016-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.4.7.2. Market Revenue and Forecast, By Application (2016-2030)
10.4.7.3. Market Revenue and Forecast, By Technology (2016-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.5.2. Market Revenue and Forecast, By Application (2016-2030)
10.5.3. Market Revenue and Forecast, By Technology (2016-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.5.4.2. Market Revenue and Forecast, By Application (2016-2030)
10.5.4.3. Market Revenue and Forecast, By Technology (2016-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, By Therapeutic Area (2016-2030)
10.5.5.2. Market Revenue and Forecast, By Application (2016-2030)
10.5.5.3. Market Revenue and Forecast, By Technology (2016-2030)
Chapter 11. Company Profiles
11.1. SGS SA
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. QuEST Global Services Pte. Ltd
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Intertek
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Element Materials Technology
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. TÜV SÜD AG
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. North American Science Associates, Inc. (NAMSA)
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Eurofins Scientific SE
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Charles River
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Sterling Medical Devices
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Pacific Biolab
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Toxikon Corporation
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Steris Laboratories
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
Glossary of Terms